Clinical trials: Disorder, Mood
Treatment-Resistant Depression
NRX-101 Expanded Access
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical…
- Trial name
- NRX-101 EAP (NCT05779267)
- Testing
- NRX-101
- Where
- United States
- Sponsor
- NeuroRx, Inc.
Bipolar Disorder
A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.
- Trial name
- NCT00282464
- Testing
- Geodon (Ziprasidone)
- Where
- 43 sites in United States
- Volunteers
- 392 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder
The purpose of this research study is to investigate a closed-loop transcranial alternating current stimulation (tACS) device to evaluate its ability to reduce symptoms of major depressive disorder
- Trial name
- NCT07282678
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Pulvinar Neuro, LLC
Bipolar Disorder
SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)
The aim of the study is to assess the tolerability, efficacy and safety of a new lithium sulphate prolonged release formulation (Lithiofor®) in patients affected by Bipolar Disorder poor tolerant to lithium immediate-release…
- Trial name
- NCT03210480
- Testing
- Lithium sulphate prolonged-release 660 mg, Lithium carbonate immediate-release 150 mg and 300 mg
- Where
- 6 sites in Italy
- Volunteers
- 85 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Bipolar Disorder
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
To evaluate the efficacy of ramelteon for treatment of acute depressive episodes associated with Bipolar 1 Disorder.
- Trial name
- NCT01677182
- Testing
- Ramelteon
- Where
- 104 sites in United States, Bulgaria and 8 more
- Volunteers
- 535 people
- Sponsor
- Takeda
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Major Depressive Disorder (MDD)
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT06836063
- Testing
- Ropanicant
- Where
- 35 sites in United States
- Volunteers
- 214 people
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder
the Safety, Tolerability, and Pharmacokinetics Study of HEC113995
Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC113995 PA•H2O in Healthy Subjects
- Trial name
- NCT04623814
- Testing
- Food, HEC113995
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Sleep Quality, Mood
A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing
This is a decentralized, single-arm, open-label clinical trial evaluating the effects of the Edge+Ease PM+AM dietary supplement system on sleep quality, mood, mental clarity, focus, and digestive comfort in 35 generally healthy…
- Conditions
- Sleep Quality, Mood, Mental Clarity, Brain Fog
- Trial name
- NCT07721506
- Testing
- Edge+ease PM
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Edge+Ease
Bipolar Disorder, Pediatric
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Efficacy and safety of asenapine for the treatment of bipolar I disorder (manic or mixed episodes) will be evaluated in participants between 10 and 17 years old, who are either hospitalized or non-hospitalized.
- Trial name
- NCT01244815
- Testing
- asenapine, Rescue medication
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00406640
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 595 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder (MDD)
Home-Based tDCS Treatment Of Major Depressive Disorder
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder.
- Trial name
- REACH-tDCS (NCT06976697)
- Testing
- Transcranial direct current stimulation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sooma Medical Inc
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250627
- Testing
- Saredutant succinate (SR48968C)
- Where
- 8 sites in Canada, Chile and 6 more
- Volunteers
- 465 people
- Sponsor
- Sanofi
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Postpartum Depression
Efficacy of MI078 Capsules in Treating Postpartum Depression
This study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants.
- Trial name
- NCT06963580
- Testing
- MI078 capsule dose 1, MI078 capsule dose 2
- Where
- 21 sites in China
- Volunteers
- 72 people
- Sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.
Depression, Bipolar
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
This is an 8-week, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood stabilizer for the treatment of patients (outpatients or…
- Trial name
- APOLLO (NCT03423680)
- Testing
- Abilify 2, 5, 10, 15mg (Tablet)
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder, Depression
Individual Patient Esmethadone (REL-1017) Expanded Access Program
To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other…
- Trial name
- NCT06009003
- Testing
- REL-1017
- Sponsor
- Relmada Therapeutics, Inc.
Depressive Disorder, Treatment-Resistant
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
This is a pre-approval access program (PAAP) for eligible participants. The main purpose of this program is to provide access to esketamine nasal spray to eligible participant with treatment-resistant depression (TRD), who have…
- Trial name
- NCT03829579
- Testing
- Esketamine
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.